SCHEMBL25138149

SCHEMBL25138149

CC(C)OC(=O)C(c1ccc(F)cc1)N1C[C@H](C)N(C(=O)OC(C)(C)C)C[C@H]1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TACR1 P25103 5/20 0.41
▸ GPR119 Q8TDV5 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC2 Q92769 2/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NR1H2 P55055 1/20 0.34
▸ NR1H3 Q13133 1/20 0.34
▸ MAPK14 Q16539 2/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25138125 0.89 TACR1 (0.40) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL21831298 0.87 TACR1 (0.39) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL30554479 0.86 TACR1 (0.38) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL23126416 0.86 TACR1 (0.38) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL21911495 0.84 TACR1 (0.38) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL29922715 0.83 MAPK14 (0.44) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL29922480 0.83 MAPK14 (0.44) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL30554491 0.83 MAPK14 (0.44) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL29922490 0.83 MAPK14 (0.44) TACR1GPR119HDAC1HDAC2MEN1
SCHEMBL26944415 0.83 MAPK14 (0.44) TACR1GPR119HDAC1HDAC2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454531-B2 Substituted piperazine derivatives useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2025-10-28 — — US disclosed
CN-115175907-B Substituted piperazine derivatives useful as T cell activators 百时美施贵宝公司 2024-08-02 — — CN disclosed
US-20230118629-A1 SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-04-20 — — US disclosed
US-20230118629-A1 SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-04-20 — — US disclosed
CN-115175907-A Substituted piperazine derivatives useful as T cell activators 百时美施贵宝公司 2022-10-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230118629-A1 SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG TACR1 1827/4885GPR119 699/4885HDAC1 803/4885
US-12454531-B2 Substituted piperazine derivatives useful as T cell activators DGKZ, DGKA, DGKG TACR1 1827/4885GPR119 699/4885HDAC1 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback